Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545537 | 0.90 | L3MBTL1 (0.41) | GAAL3MBTL1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL3547224 | 0.72 | HSD17B10 (0.38) | L3MBTL1KDM4EPOLBTSHRHSD17B10 | |
| SCHEMBL23929061 | 0.71 | SMN1; SMN2 (0.82) | RXFP1KDM4EPOLBTSHRSMN1; SMN2 | |
| SCHEMBL84933 | 0.70 | TSHR (0.59) | POLBTSHRSMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL3545618 | 0.69 | TSHR (0.43) | GAAKDM4EPOLBTSHRSMN1; SMN2 | |
| SCHEMBL9299116 | 0.68 | SMN1; SMN2 (0.70) | RXFP1KDM4EPOLBTSHRSMN1; SMN2 | |
| SCHEMBL85431 | 0.67 | TSHR (0.60) | POLBTSHRSMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL3542513 | 0.67 | OPRM1 (0.40) | GAAL3MBTL1RXFP1KDM4ETP53 | |
| Hydrochloric Acid SCHEMBL5843426 | 0.66 | TSHR (0.62) | POLBTSHRSMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL22317521 | 0.66 | POLB (0.55) | POLBTSHRSMN1; SMN2HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | GAA 1461/4885L3MBTL1 3206/4885RXFP1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.